Urovant Sciences (Nasdaq: UROV), a clinical-stage
biopharmaceutical company developing and commercializing innovative
therapies for urologic conditions, today announced Chief Executive
Officer Keith A. Katkin will present at the annual Roivant Pipeline Day
on June 6, 2019 at 1:50 p.m. ET.
A live webcast for this event will be available on the Investor
Relations section of the Urovant website at http://ir.urovant.com.
A replay will be available for approximately 3 months.
About Roivant Pipeline Day
Roivant Pipeline Day will be held on Thursday, June 6, 2019 in New York
City. The event will feature presentations and Q&A sessions from
executives across the Roivant family of companies highlighting new
clinical data and investments in technology. The event is scheduled to
begin at 1:00 p.m. ET and will continue until approximately 4:30 p.m.
ET. A live webcast will be available to interested parties. To request
access to the webcast or to learn more about the event, please email email@example.com.
About Urovant Sciences
Urovant Sciences is a clinical-stage biopharmaceutical company focused
on developing and commercializing innovative therapies for urologic
conditions. Urovant recently reported positive Phase 3 trial results for
its lead product candidate, vibegron, an oral, once-daily small molecule
beta-3 agonist being evaluated for overactive bladder (OAB). The
international, pivotal trial achieved co-primary endpoints and all seven
key secondary endpoints. In addition, vibegron is being evaluated in a
phase 3 study for the treatment of OAB in men with benign prostatic
hyperplasia and in a phase 2a study for abdominal pain associated with
irritable bowel syndrome. Urovant’s second product candidate, URO-902,
is a novel gene therapy being developed for patients with OAB who have
failed oral pharmacological therapy. Urovant Sciences, a subsidiary of
Roivant Sciences, Ltd., intends to develop treatments for additional
urologic diseases. Learn more about us at www.urovant.com.
About Roivant Sciences
Roivant aims to improve health by rapidly delivering innovative
medicines and technologies to patients. Roivant does this by building
Vants – nimble, entrepreneurial biotech and healthcare technology
companies with a unique approach to sourcing talent, aligning
incentives, and deploying technology to drive greater efficiency in R&D
and commercialization. For more information, please visit www.roivant.com